Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Biomarker; Therapeutic Use
- 08 Jan 2018 Status changed from completed to discontinued.
- 11 Mar 2017 Status changed from active, no longer recruiting to completed.
- 19 Apr 2015 Planned End Date changed from 1 Aug 2016 to 1 April 2018 as reported by ClinicalTrials.gov record.